SAN DIEGO, Jul 16, 2010 (BUSINESS WIRE) --
Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of B. Melina Cimler, Ph.D., as Vice President, Quality and Regulatory Affairs, reporting to Christian Henry, Senior Vice President, Chief Financial Officer and General Manager, Life Sciences. Dr. Cimler will lead Illumina's quality and regulatory organizations to support the development, manufacture and distribution of products serving the research, consumer and molecular diagnostic markets.
"We are delighted to welcome Dr. Cimler to Illumina," said Mr. Henry. "She brings an impressive breadth of leadership experience in the quality and regulatory areas. I expect she will play a key role as we continue to scale our life sciences business and expand into diagnostics."
Prior to joining Illumina, Dr. Cimler served as President of PandiaDx Consulting, where she provided regulatory and compliance guidance for the development of in vitro diagnostics products and medical devices. Previously, she held leadership positions in quality, regulatory and government affairs at Beckman Coulter Inc. She also served in senior quality and regulatory roles at Abbott Molecular and Gen-Probe Inc. Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.
About Dr. Cimler's Compensation
Illumina granted an option to purchase 120,000 shares of Illumina's common stock to Dr. Cimler as part of her inducement to join the company. The options were granted by Illumina's Compensation Committee pursuant to NASDAQ Marketplace Rule 5635(c)(4) and under Illumina's New Hire Stock and Incentive Plan, which was approved by Illumina's Board of Directors on January 29, 2008. The option has the following terms: an exercise price equal to the closing fair market value of Illumina's common stock on the grant date, a ten-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter. The grant date for the option to Dr. Cimler is July 12, 2010.
For more information about careers at Illumina, please visit http://www.illumina.com/careers.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com
